Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian...

Area of Science:

• Pharmacogenomics
• Oncology
• Clinical Pharmacology

Background:

• Tamoxifen is a standard treatment for premenopausal women with estrogen receptor-positive (ER+) breast cancer.
• Tamoxifen's effectiveness depends on its metabolism by CYP2D6, CYP2C19, and CYP3A4 enzymes.
• Concomitant medications inhibiting these enzymes may alter tamoxifen's therapeutic effect.

Purpose of the Study:

• To investigate the impact of co-prescribed CYP enzyme-inhibiting drugs on breast cancer recurrence in premenopausal women treated with tamoxifen.
• To evaluate the association between drug-drug interactions affecting tamoxifen metabolism and breast cancer recurrence risk.

Main Methods:

• A cohort study of 4493 premenopausal women with ER+ breast cancer treated with tamoxifen between 2002-2011.
• Time-varying CYP inhibitor exposure was defined as the proportion of overlapping days with tamoxifen treatment.
• Associations were estimated using Bayesian joint modeling and traditional Cox regression.

Main Results:

• Bayesian models indicated a potential increase in recurrence risk with substantial CYP2D6 inhibitor use (HR: 1.24, 95% CrI: 0.96, 1.58).
• No significant recurrence association was observed for CYP2C19 or CYP3A4/5 inhibitors using Bayesian models.
• Cox regression models produced less reliable results, showing a positive association for CYP2C19 inhibitors.

Conclusions:

• Bayesian joint modeling suggests a slight increase in breast cancer recurrence associated with CYP2D6 inhibitor use during tamoxifen therapy.
• No significant association between CYP2C19 or CYP3A4/5 inhibitor use and recurrence was found using Bayesian methods.
• Bayesian joint modeling provided more plausible results compared to traditional Cox regression for evaluating drug-drug interactions in this context.